Zomedica Pharmaceuticals Corp.
100 Phoenix Drive, Suite 190
Ann Arbor, MI 48108
January 28, 2019
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re: | Zomedica Pharmaceuticals Corp. |
Registration Statement on Form S-3 (File No. 333-228926)
Filed on December 20, 2018
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, Zomedica Pharmaceuticals Corp. (the “Company”) hereby requests that the above-referenced Registration Statement (the “Registration Statement”) be declared effective by the Securities and Exchange Commission (the “Commission”) at 5:00 p.m., Eastern Time, on January 30, 2019, or as soon as practicable thereafter.
Please call John D. Hogoboom of Lowenstein Sandler LLP at (973) 597-2382 to confirm the effectiveness of the Registration Statement or with any questions.
[Signature page follows.]
U.S. Securities and Exchange Commission
January 28, 2019
Page 2
Very truly yours, | |||
ZOMEDICA PHARMACEUTICALS CORP. | |||
By: | /s/ Gerald Solensky, Jr. | ||
Name: | Gerald Solensky, Jr. | ||
Title: | Chairman of the Board, President and Chief Executive Officer |
-2-